OVOL1 is a C2H2 zinc finger transcription factor that functions as a critical regulator of epithelial differentiation and barrier homeostasis. As a direct transcriptional target of the aryl hydrocarbon receptor (AhR) in keratinocytes, OVOL1 controls a regulatory axis with downstream target Id1 that promotes epidermal barrier function and immune homeostasis 1. OVOL1 regulates the expression of skin barrier proteins, particularly filaggrin (FLG), and is involved in glucose-dependent mRNA splicing of pro-differentiation genes during tissue differentiation 2. Mechanistically, OVOL1 acts downstream of the IL-13 signaling pathway, where IL-13-mediated downregulation of the OVOL1-FLG axis contributes to barrier dysfunction in atopic dermatitis 3. OVOL1 can inhibit epithelial-mesenchymal transition and regulate cancer cell stemness, influencing metastasis and differentiation states 4. Loss-of-function mutations and dysregulation of OVOL1 impair epidermal barrier integrity and are associated with increased susceptibility to atopic dermatitis and psoriasis 5, 6. OVOL1 variants have been identified as risk loci for IgA nephropathy, suggesting broader roles beyond skin 7. Therapeutically, OVOL1 represents a potential target for treating inflammatory skin diseases, with agonists showing promise in barrier restoration.